US2015050257A1PendingUtilityA1
Fibrosis causing agent
Est. expiryAug 19, 2033(~7.1 yrs left)· nominal 20-yr term from priority
A61P 43/00A61K 35/19A61K 9/007A61K 38/363A61K 31/734A61P 11/00A61K 47/02A61K 35/16A61K 45/06A61K 38/4833
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A fibrosis-causing agent is highly effective in the fibrosis of tissues. The fibrosis-causing agent contains a fibrosis inducer and a fibrosis promoter. A fibrosis-causing agent dosage form and a method of administering the fibrosis-causing agent is also disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter.
2 . The fibrosis-causing agent according to claim 1 , wherein the fibrosis promoter contains platelets or platelet-rich plasma (PRP).
3 . The fibrosis-causing agent according to claim 2 , wherein the fibrosis promoter contains platelet-rich plasma (PRP) and a PRP gelling agent.
4 . The fibrosis-causing agent according to claim 3 , wherein PRP gelling agent contains at least one selected from the group consisting of calcium, calcium salt, fibrin, fibrinogen, thrombin, vitamin K, and factor X.
5 . The fibrosis-causing agent according to claim 1 , wherein the fibrosis inducer contains at least one polyanion.
6 . The fibrosis-causing agent according to claim 5 , wherein the polyanion is at least one selected from the group consisting of alginic acid, alginate, and alginic ester.
7 . The fibrosis-causing agent according to claim 1 , wherein the fibrosis-causing agent is administered for treatment of pulmonary emphysema.
8 . A method of causing fibrosis by administering to a patient in thereof, a fibrosis causing agent according to claim 1 .
9 . A method for causing fibrosis by administering to a subject a fibrosis causing agent.
10 . The method according to claim 9 , wherein the fibrosis causing agent comprises a fibrosis inducer and a fibrosis promoter.
11 . The method according to claim 10 , wherein the fibrosis promoter contains platelets or platelet-rich plasma (PRP).
12 . The method according to claim 11 , wherein the fibrosis promoter contains platelet-rich plasma (PRP) and a PRP gelling agent.
13 . The method according to claim 12 , wherein PRP gelling agent contains at least one selected from the group consisting of calcium, calcium salt, fibrin, fibrinogen, thrombin, vitamin K, and factor X.
14 . The method according to claim 9 , wherein the fibrosis inducer contains at least one polyanion.
15 . The method according to claim 14 , wherein the polyanion is at least one selected from the group consisting of alginic acid, alginate, and alginic ester.
16 . A composition for treating pulmonary emphysema, the composition consisting of a fibrosis-causing agent, the fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter.
17 . A method for treating pulmonary emphysema by administering to a patient in need thereof, the composition according to claim 16 .
18 . A fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter,
the fibrosis promoter consisting essentially of platelets or platelet-rich plasma (PRP); and the fibrosis inducer consisting essentially of at least one polyaninon.
19 . The fibrosis-causing agent according to claim 18 , wherein the fibrosis promoter further comprises a platelet-rich plasma (PRP) gelling agent, the gelling agent is at least one selected from the group consisting of calcium, calcium salt, fibrin, fibrinogen, thrombin, vitamin K, and factor X.
20 . The fibrosis causing agent according to claim 18 , wherein the polyanion is at least one selected from the group consisting alginic acid, alginate and alginic ester.
21 . A fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter, wherein
the fibrosis promoter is platelet-rich plasma (PRP); and the fibrosis inducer is calcium alginate.Join the waitlist — get patent alerts
Track US2015050257A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.